David N. WATKINS,Kieren D. MARINI,David Morritz DE KRETSER
申请号：
US15564183
公开号：
US20180125936A1
申请日:
2016.03.23
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates generally to a method of treating a neoplastic condition. More particularly, the present invention is directed to a method of selectively sensitising neoplastic cells prior to chemotherapy. The method of the present invention is predicated on administering chemotherapy treatment subsequently to neoplastic cell sensitisation via the exposure of these cells to an activin type 1 B receptor (ACVR1B) antagonist. The present findings have now enabled the development of a new neoplastic treatment regime exhibiting both higher efficacy and reduced side effects for patients and, still further, a means of effectively treating chemoresistant neoplasms.
